Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab and ATRA in steroid-resistant/relapsed ITP
NCT03304288Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tretinoin in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response at 1 year. Status: unknown.
02
Drugs
tretinoin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03304288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304288.